Crucell will present a comprehensive update on the Company's strategy, product development and clinical development progress, including the most recently available data on its product programs.
Analysts and institutional investors who would like to attend the meeting should confirm their attendance via email to b.mulder@crucell.com before November 3, 2006.
The meeting will be webcast live via the homepage of Crucell's website at http://www.crucell.com. The webcast will also be archived and available for replay following the event. The meeting is expected to last approximately three hours.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
For further information please contact:
|
Crucell N.V.
Paul Vermeij
Director Investor Relations and Corporate Communications
Tel. +31-(0)71-524 8718
Mob. +31-(0)6-55364830
To confirm attendance at the Analyst meeting:
Barbara Mulder
Coordinator Investor Relations
|
For Crucell in the US:
Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
|